Shots:

• The P-II MOONSONG trial evaluates the antiviral activity- safety & PK of AT-527 (550/1100 mg- bid) vs PBO in adult patients with COVID-19. The therapy is jointly developed in collaboration with Roche
• The trial did not meet its 1EPs of reduction from baseline in SARS-CoV-2 virus in an overall study population- two-thirds of patients had low-risk with mild symptoms. In high-risk patients- a reduction of viral load of ~0.5 log10 @ 7 Day was observed at both doses- was generally safe & well tolerated
• AT-527 is non-mutagenic & has no effects on fertility & reproduction. The therapy is being evaluated across multiple P-II & III clinical trials & P-III MORNINGSKY data is expected in H2’22

  | Ref: Atea Pharma | Image: Atea Pharma